



PROVIDER ALERT

ZUBSOLV CHANGE OVER INFORMATION

JUNE 22, 2016

As you know starting July 1, 2016, Maryland Medicaid will make Zubsolv® sublingual tablets preferred on the Department's Preferred Drug List (PDL), whereas the Suboxone® Film will become non-preferred. Prescriptions for Suboxone® Film will deny at the pharmacy as of 7/1/2016 unless a prior authorization is submitted by the prescriber.

To assist patients in their transition from Suboxone® film to Zubsolv® tablets, the manufacturer of Zubsolv®, Orexo, will have informational Webex programs for prescribers to learn about this form of buprenorphine and naloxonesublingual tablets (CIII).

As with any prescription drug, the Department expects prescribers to provide clinically appropriate interventions with their patients and to educate themselves and their patients to successfully transition to the tablets as listed on the Department's PDL. For prescribers who need additional time to facilitate the transition with their patients, please contact Xerox at 1-800-932-3918 for a prior authorization. Xerox will approve a one (1) time PDL fill of the current Suboxone® Film prescription.

Prescribers starting patients on Buprenorphine and Naloxone treatment after July 1, 2016 should refer to the Department's PDL.

Webinars are available to learn more about Zubsolv®. Information regarding the webinars can be found at this link:

<http://dhmh.maryland.gov/bhd/Pages/Integration-Efforts.aspx>.